Single Photon Emission Computerized Tomography With Capromab Pendetide Plus Computerized Tomography Image Set Co-Registration Independently Predicts Biochemical Failure

Ellis, Rodney J.; Zhou, Esther H.; Fu, Ping; Kaminsky, Deborah A.; Sodee, D. Bruce; Faulhaber, Peter; Bodner, Donald R.; Resnick, Martin I.

doi:10.1016/j.juro.2008.01.025

Cited by 20 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eventually, predictive modeling and improved imaging may enable prostate brachytherapists to tailor treatment margins on a case by case basis [18, 19]. Until these technologies become available, a 3-5 mm periprostatic treatment margin appears prudent [6, 9, 16].…”

Section: Discussionmentioning

confidence: 99%

Permanent prostate brachytherapy extracapsular radiation dose distributions: analysis of a multi-institutional database

Merrick

Butler²,

Grimm³

et al. 2013

jcb

View full text Add to dashboard Cite

PurposePeriprostatic brachytherapy doses impact biochemical control. In this study, we evaluate extracapsular volumetric dosimetry following permanent prostate brachytherapy in patients entered in a multi-institutional community database.Material and methodsIn the database, 4547 patients underwent brachytherapy (3094 – 125I, 1437 – 103Pd and 16 – 131Cs). Using the originally determined prostate volume, a 5 mm, 3-dimensional peri-prostatic anulus was constructed around the prostate (except for a 2 mm posterior margin), and evaluated in its entirety and in 90° segments. Prostate dosimetric parameters consisted of a V100 and D90 while the annular dosimetry was reported as a V100.ResultsThe intraprostatic V100 and D90 for 103Pd, and 125I were statistically comparable when stratified by isotope and/or monotherapy vs. boost. The overall mean V100 for the periprostatic annulus was 62.8%. The mean V100 at the base (51.6%) was substantially less than the apex (73.5%) and midgland (65.9%). In addition, for all patients, the anterior V100 (45.7%) was less than the lateral (68.8%) and the posterior (75.0%). The geometric V100 annular differences were consistent when evaluated by isotope. Overall, the V100 was higher in the 125I cohort.ConclusionsThe optimal extracapsular brachytherapy dose and radial extent remains unknown, but will prove increasingly important with reductions and/or elimination of supplemental external beam radiation therapy. The large multi-institutional community database demonstrates periprostatic annular doses that are not as robust as those in selected high volume brachytherapy centers, and may be inadequate for optimal biochemical control following monotherapeutic brachytherapy, especially in higher risk patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Permanent prostate brachytherapy extracapsular radiation dose distributions: analysis of a multi-institutional database

Merrick

Butler²,

Grimm³

et al. 2013

jcb

View full text Add to dashboard Cite

show abstract

“…Ellis et al have suggested that pretreatment immuno-scintigraphy SPECT-CT may suggest regions where the usual margin of 2-3 mm should be extended in a nonuniform manner at the time of planning (35). Our ongoing efforts to fuse postimplantation dosimetry with MR spectroscopy of local failures may help to elucidate the relationship between intraprostatic dosimetry and local recurrence.…”

Section: Discussionmentioning

confidence: 99%

Magnetic Resonance Imaging–Defined Treatment Margins in Iodine-125 Prostate Brachytherapy

Crook

Patil

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…21,176 This feasibility study was also supported by the SPECT/CT studies of 111 In-ProstaScint for the patients presented with clinically localized cancer, which found that the biochemical failure from radiotherapy was higher for the group of patients who had extra-periprostatic metastasis versus the group of patients who had confined localized cancer by the 111 In-ProstaScint SPECT/CT findings. 177 Although it is still controversial and not generally accepted, the prognostic value of quantitative 111 In-ProstaScint SPECT/CT imaging findings could be highly relevant and correlative with the cancer prognostic factor such as pathologic Gleason score. 178 The prognostic value of this imaging study will likely be strengthened when a more robust PSMA-targeting radionuclide imaging agent can be used in human subjects.…”

Section: Radionuclide Imaging Of Prostate Cancer and Therapeutic Implmentioning

confidence: 99%

Functional Imaging for Prostate Cancer: Therapeutic Implications

Aparici

Seo

2012

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Functional radionuclide imaging modalities, now commonly combined with anatomical imaging modalities CT or MRI (SPECT/CT, PET/CT, and PET/MRI) are promising tools for the management of prostate cancer particularly for therapeutic implications. Sensitive detection capability of prostate cancer using these imaging modalities is one issue; however, the treatment of prostate cancer using the information that can be obtained from functional radionuclide imaging techniques is another challenging area. There are not many SPECT or PET radiotracers that can cover the full spectrum of the management of prostate cancer from initial detection, to staging, prognosis predictor, and all the way to treatment response assessment. However, when used appropriately, the information from functional radionuclide imaging improves, and sometimes significantly changes, the whole course of the cancer management. The limitations of using SPECT and PET radiotracers with regards to therapeutic implications are not so much different from their limitations solely for the task of detecting prostate cancer; however, the specific imaging target and how this target is reliably imaged by SPECT and PET can potentially make significant impact in the treatment of prostate cancer. Finally, while the localized prostate cancer is considered manageable, there is still significant need for improvement in noninvasive imaging of metastatic prostate cancer, in treatment guidance, and in response assessment from functional imaging including radionuclide-based techniques. In this review article, we present the rationale of using functional radionuclide imaging and the therapeutic implications for each of radionuclide imaging agent that have been studied in human subjects.

show abstract

Single Photon Emission Computerized Tomography With Capromab Pendetide Plus Computerized Tomography Image Set Co-Registration Independently Predicts Biochemical Failure

Abstract: Unconfirmed findings of extra-periprostatic metastatic prostate cancer on SPECT/CT immunoscintigraphy independently and significantly predicted an increased risk of biochemical failure in patients presenting for radiotherapy with a clinical diagnosis of localized prostate cancer.

Cited by 20 publications

References 12 publications

Permanent prostate brachytherapy extracapsular radiation dose distributions: analysis of a multi-institutional database

Permanent prostate brachytherapy extracapsular radiation dose distributions: analysis of a multi-institutional database

Magnetic Resonance Imaging–Defined Treatment Margins in Iodine-125 Prostate Brachytherapy

Functional Imaging for Prostate Cancer: Therapeutic Implications

Contact Info

Product

Resources

About